免疫治疗与放疗协同作用的临床证据（SITAR）。
Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR).
机构信息
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
University of Western Australia, Crawley, Western Australia, Australia.
出版信息
J Med Imaging Radiat Oncol. 2022 Sep;66(6):881-895. doi: 10.1111/1754-9485.13441. Epub 2022 Jun 14.
Abstract
Previous preclinical and clinical trials have shown promising antitumour activity and toxicity profile when employing the 'Synergy between Immunotherapy and Radiotherapy' (SITAR) strategy. Approximately, one in seven radiation therapy studies currently recruiting is investigating SITAR. This article reviews the range of cancers known to respond to immunotherapy and publications analysing SITAR. It sets the background for work that needs to be done in future clinical trials. It also reviews the potential toxicities of immunotherapy and discusses areas where caution is required when combining treatments.
摘要
先前的临床前和临床试验表明，采用“免疫治疗与放射治疗协同作用”（SITAR）策略具有有前景的抗肿瘤活性和毒性特征。目前大约有七分之一正在招募的放射治疗研究正在研究 SITAR。本文综述了已知对免疫疗法有反应的各种癌症以及分析 SITAR 的出版物。它为未来临床试验需要开展的工作奠定了基础。它还综述了免疫疗法的潜在毒性，并讨论了在联合治疗时需要谨慎的领域。
相似文献
1
Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR).免疫治疗与放疗协同作用的临床证据（SITAR）。
J Med Imaging Radiat Oncol. 2022 Sep;66(6):881-895. doi: 10.1111/1754-9485.13441. Epub 2022 Jun 14.
2
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?免疫疗法与立体定向消融放疗（ISABR）：一种治愈性方法？
Nat Rev Clin Oncol. 2016 Aug;13(8):516-24. doi: 10.1038/nrclinonc.2016.30. Epub 2016 Mar 8.
3
Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization.协同放化疗和免疫治疗：当前的挑战和优化策略。
Neoplasia. 2023 Feb;36:100867. doi: 10.1016/j.neo.2022.100867. Epub 2022 Dec 21.
4
Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies.免疫治疗联合放疗治疗泌尿生殖系统恶性肿瘤。
Eur Urol Oncol. 2019 Feb;2(1):79-87. doi: 10.1016/j.euo.2018.09.013. Epub 2018 Nov 16.
5
Combined Radiotherapy and New Systemic Therapies - Have We Moved Beyond Palliation?联合放化疗与新型全身治疗——我们是否已超越姑息治疗？
Clin Oncol (R Coll Radiol). 2020 Nov;32(11):758-765. doi: 10.1016/j.clon.2020.07.021. Epub 2020 Aug 27.
6
Emerging evidence for adapting radiotherapy to immunotherapy.新兴证据表明放疗与免疫疗法相结合具有优势。
Nat Rev Clin Oncol. 2023 Aug;20(8):543-557. doi: 10.1038/s41571-023-00782-x. Epub 2023 Jun 6.
7
Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours.立体定向消融放疗（SABR）联合免疫治疗：转移性实体瘤个体化治疗的挑战
J Transl Med. 2012 May 22;10:104. doi: 10.1186/1479-5876-10-104.
8
Immunotherapy and Radiation: Charting a Path Forward Together.免疫疗法与放射治疗：携手前行的路径
Hematol Oncol Clin North Am. 2019 Dec;33(6):1057-1069. doi: 10.1016/j.hoc.2019.08.001. Epub 2019 Sep 17.
9
Immunotherapy and radiotherapy for metastatic cancers.转移性癌症的免疫疗法和放射疗法。
Ann Palliat Med. 2019 Jul;8(3):312-325. doi: 10.21037/apm.2018.07.10. Epub 2018 Aug 22.
10
Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?免疫疗法与放射疗法联合治疗妇科肿瘤的临床试验：是否具有协同作用？
Gynecol Oncol. 2019 Jul;154(1):236-245. doi: 10.1016/j.ygyno.2019.03.255. Epub 2019 Apr 14.
引用本文的文献
1
Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities.利用放射疗法改善免疫治疗效果：原理、进展与研究重点
Clin Transl Immunology. 2025 Apr 8;14(4):e70030. doi: 10.1002/cti2.70030. eCollection 2025.
2
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.帕博利珠单抗、放疗和手术与放疗和手术治疗肢体 III 期软组织肉瘤（SU2C-SARC032）的安全性和有效性：一项开放标签、随机临床试验。
Lancet. 2024 Nov 23;404(10467):2053-2064. doi: 10.1016/S0140-6736(24)01812-9. Epub 2024 Nov 12.
3
Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis.癌症放射治疗联合免疫治疗的全球研究格局与趋势：一项文献计量分析。
Heliyon. 2024 Feb 27;10(5):e27103. doi: 10.1016/j.heliyon.2024.e27103. eCollection 2024 Mar 15.
4
Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis.血管周上皮样细胞肿瘤的系统治疗和分子标志物：单中心回顾性分析。
Cancer Res Commun. 2023 Jul 12;3(7):1212-1223. doi: 10.1158/2767-9764.CRC-23-0139. eCollection 2023 Jul.
5
Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors.德克萨斯州转移性黑色素瘤的管理：免疫检查点抑制剂监管批准后免疫疗法利用的差异。
BMC Cancer. 2023 Jul 13;23(1):655. doi: 10.1186/s12885-023-11142-4.
6
Introducing Radiotherapy in Metastatic Merkel Cell Carcinoma Patients with Limited Progression on Avelumab: An Effective Step against Primary and Secondary Immune Resistance?在接受阿维鲁单抗治疗后疾病进展有限的转移性默克尔细胞癌患者中引入放射治疗：对抗原发性和继发性免疫抵抗的有效措施？
J Pers Med. 2023 May 17;13(5):841. doi: 10.3390/jpm13050841.
7
Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player.放射治疗、PARP抑制和免疫检查点阻断：克服单一治疗双刃剑效应的三联疗法。
Cancers (Basel). 2023 Feb 8;15(4):1093. doi: 10.3390/cancers15041093.
8
Immune marker expression of irradiated mesothelioma cell lines.辐射后的间皮瘤细胞系的免疫标志物表达。
Front Oncol. 2022 Oct 31;12:1020493. doi: 10.3389/fonc.2022.1020493. eCollection 2022.
9
Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.显著 HCC 方案：替雷利珠单抗联合立体定向体部放疗新辅助治疗可切除肝细胞癌的 Ib 期研究。
BMJ Open. 2022 Sep 17;12(9):e060955. doi: 10.1136/bmjopen-2022-060955.
本文引用的文献
1
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.寡转移肾细胞癌的立体定向放疗和短期帕博利珠单抗治疗：RAPPORT 试验。
Eur Urol. 2022 Apr;81(4):364-372. doi: 10.1016/j.eururo.2021.12.006. Epub 2021 Dec 23.
2
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.纳武利尤单抗联合立体定向放疗治疗预处理转移性肾细胞癌患者：Ⅱ期 NIVES 研究结果。
Eur Urol. 2022 Mar;81(3):274-282. doi: 10.1016/j.eururo.2021.09.016. Epub 2021 Oct 1.
3
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.一项在 IV 期 NSCLC 患者中同步或序贯使用伊匹单抗、纳武利尤单抗和立体定向体部放疗的 1 期临床试验研究。
J Thorac Oncol. 2022 Jan;17(1):130-140. doi: 10.1016/j.jtho.2021.08.019. Epub 2021 Sep 6.
4
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.avelumab 联合立体定向消融体放射治疗转移性去势抵抗性前列腺癌：ICE-PAC 阶段 2 临床试验。
Eur Urol. 2022 Mar;81(3):253-262. doi: 10.1016/j.eururo.2021.08.011. Epub 2021 Sep 4.
5
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.低剂量放疗逆转肿瘤免疫荒漠化并克服免疫治疗抵抗。
Cancer Discov. 2022 Jan;12(1):108-133. doi: 10.1158/2159-8290.CD-21-0003. Epub 2021 Sep 3.
6
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.晚期非小细胞肺癌患者使用放射性标记的度伐利尤单抗进行PD-L1 PET/CT成像
J Nucl Med. 2022 May;63(5):686-693. doi: 10.2967/jnumed.121.262473. Epub 2021 Aug 12.
7
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.avelumab 一线治疗 116 例转移性 Merkel 细胞癌患者（JAVELIN Merkel 200 研究）：Ⅱ期研究的主要和生物标志物分析。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002646.
8
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.立体定向体部放疗联合帕博利珠单抗和曲美替尼与立体定向体部放疗联合吉西他滨治疗手术切除后局部复发性胰腺癌：一项开放标签、随机、对照、2 期临床试验。
Lancet Oncol. 2021 Aug;22(8):1093-1102. doi: 10.1016/S1470-2045(21)00286-2. Epub 2021 Jul 5.
9
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.局部晚期直肠癌新辅助治疗的应用：帕博利珠单抗在 2 期随机临床试验中的初步结果。
JAMA Oncol. 2021 Aug 1;7(8):1225-1230. doi: 10.1001/jamaoncol.2021.1683.
10
Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus.转移性疾病患者治疗中的放疗与免疫治疗联合：现状与未来重点
Clin Cancer Res. 2021 Oct 1;27(19):5188-5194. doi: 10.1158/1078-0432.CCR-21-0145.
Zotero 插件